Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ofatumumab works safely for elderly patients with CLL, comorbidities

Publish date:: January 22, 2020

Key clinical point: For elderly patients with chronic lymphocytic leukemia and comorbidities, the anti-CD20 monoclonal antibody ofatumumab may be a safe and effective treatment option.

Major finding: The overall response rate was 72%.

Study details: A phase 2 trial involving 34 elderly patients with chronic lymphocytic leukemia.

Disclosures: The study was funded by Novartis, which markets the antibody. The investigators reported additional relationships with AbbVie, Roche, Celgene, and others.

Citation:

Vitale et al. J Geriatr Oncol. 2019 Apr 18. doi: 10.1016/j.jgo.2019.04.002.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,